|
ハセガワ タイジ
HASEGAWA Taiji
長谷川 泰司 所属 医学部 医学科（東京女子医科大学病院） 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion. |
| 掲載誌名 | 正式名：The British journal of ophthalmology 略 称：Br J Ophthalmol ISSNコード：14682079/00071161 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 103(1),pp.72-77 |
| 著者・共著者 | Hasegawa Taiji, Murakawa Sakura, Maruko Ichiro, Kogure-Katakura Akiko, Iida Tomohiro |
| 担当区分 | 筆頭著者,責任著者 |
| 発行年月 | 2019/01 |
| 概要 | AIM:To determine whether there is a significant correlation between the reduction in macular vessel density and the recurrence of macular oedema in eyes with branch retinal vein occlusion (BRVO).METHODS:We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in the recurrence group. The macular vessel density in 3×3 mm area centred on the fovea was determined by optical coherence tomography angiography.RESULTS:At 12 months, 11 of the 27 (40.7%) eyes were placed in the resolved group and the other 16 (59.3%) eyes were placed in the recurrence group. The mean macular vessel density reduction in the resolved group was 17.60%±7.88% and that in the recurrence group was 8.12%±7.48% (P=0.0042). The mean number of IVR injections in the resolved group was 2.1±1.1 and that in the recurrence group was 5.1±1.2 (P<0.0001). In all eyes, multivariate analysis showed that the reduction in macular vessel density was significantly and negatively correlated with the number of IVR injections (β=-0.6746, P=0.0028).CONCLUSIONS:A reduction in the macular vessel density was significantly correlated with the number of recurrences of macular oedema associated with BRVO. |
| DOI | 10.1136/bjophthalmol-2017-311499 |
| PMID | 29545416 |